- Home
- XERS vs BHRB Comparison
XERS vs BHRB Comparison
Compare XERS & BHRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XERS | BHRB |
|---|---|---|
| Founded | 2005 | 1852 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 965.6M | 968.8M |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | XERS | BHRB |
|---|---|---|
| Price | $5.47 | $61.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $10.43 | ★ $72.50 |
| AVG Volume (30 Days) | ★ 2.1M | 53.6K |
| Earning Date | 05-18-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 3.55% |
| EPS Growth | 100.00 | ★ 173.76 |
| EPS | N/A | ★ 7.72 |
| Revenue | ★ $49,590,000.00 | N/A |
| Revenue This Year | $28.65 | $36.62 |
| Revenue Next Year | $18.33 | $10.06 |
| P/E Ratio | ★ N/A | $8.03 |
| Revenue Growth | ★ 142.67 | N/A |
| 52 Week Low | $3.81 | $47.77 |
| 52 Week High | $10.08 | $70.90 |
Technical Indicators
Market Signals| Indicator | XERS | BHRB |
|---|---|---|
| Relative Strength Index (RSI) | 26.31 | 33.19 |
| Support Level | $4.30 | $58.14 |
| Resistance Level | $5.49 | $62.85 |
| Average True Range (ATR) | 0.34 | 1.82 |
| MACD | -0.06 | -0.50 |
| Stochastic Oscillator | 3.62 | 15.21 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
About BHRB Burke & Herbert Financial Services Corp.
Burke & Herbert Financial Services Corp is the bank holding company. Through its subsidiary, it predominantly serves small to medium-sized businesses, their owners and employees, professional corporations, non-profits, and individuals with various banking products and financial services. Some of its products and service offerings include checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential mortgage, acquisition, construction, and development loans, online banking, mobile banking, and wealth and trust services. The company operates in a single segment, namely Community Banking.